Compare TAP & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAP | SYRE |
|---|---|---|
| Founded | 1873 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.5B |
| IPO Year | 1994 | 2015 |
| Metric | TAP | SYRE |
|---|---|---|
| Price | $42.21 | $95.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 12 |
| Target Price | $48.94 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 2.7M | 795.7K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $11,723,800,000.00 | N/A |
| Revenue This Year | $0.85 | N/A |
| Revenue Next Year | $0.17 | N/A |
| P/E Ratio | $20.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.04 | $14.51 |
| 52 Week High | $54.82 | $110.18 |
| Indicator | TAP | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 38.06 |
| Support Level | $40.53 | $66.78 |
| Resistance Level | $43.65 | $106.10 |
| Average True Range (ATR) | 1.01 | 4.57 |
| MACD | -0.04 | -1.11 |
| Stochastic Oscillator | 46.34 | 12.26 |
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling, and ranks as the second-largest beer maker in both value and volume in the US, Canada, and the United Kingdom. Through licensing agreements, it also brews and distributes beer and nonbeer beverage categories under partner brands from Heineken, Anheuser-Busch InBev, Asahi, Fever-Tree, and Coca-Cola. North America remains its largest market, accounting for nearly 80% of total revenue.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.